Total Payments
$909,137
2024 Payments
$146,033
Companies
26
Transactions
567
Medicare Patients
158
Medicare Billing
$16,771
Payment Breakdown by Category
Consulting$587,245 (64.6%)
Travel$220,140 (24.2%)
Other$85,574 (9.4%)
Food & Beverage$9,129 (1.0%)
Research$7,049 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $587,245 | 170 | 64.6% |
| Travel and Lodging | $220,140 | 205 | 24.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $85,574 | 19 | 9.4% |
| Food and Beverage | $9,129 | 168 | 1.0% |
| Unspecified | $7,049 | 5 | 0.8% |
Payments by Type
General
$902,088
562 transactions
Research
$7,049
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $336,842 | 223 | $0 (2024) |
| GENZYME CORPORATION | $132,213 | 48 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $105,904 | 92 | $0 (2024) |
| AstraZeneca AB | $46,079 | 43 | $0 (2024) |
| AstraZeneca UK Limited | $43,665 | 29 | $0 (2024) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $41,994 | 21 | $0 (2017) |
| Boehringer Ingelheim International GmbH | $40,718 | 24 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $40,371 | 11 | $0 (2022) |
| SANOFI US SERVICES INC. | $25,256 | 2 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $17,690 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $146,033 | 76 | AstraZeneca Pharmaceuticals LP ($37,140) |
| 2023 | $157,626 | 85 | GENZYME CORPORATION ($86,461) |
| 2022 | $44,348 | 15 | GlaxoSmithKline, LLC. ($27,361) |
| 2021 | $87,744 | 31 | GENZYME CORPORATION ($15,321) |
| 2020 | $91,065 | 27 | GlaxoSmithKline, LLC. ($38,760) |
| 2019 | $125,582 | 138 | GlaxoSmithKline, LLC. ($50,134) |
| 2018 | $119,461 | 105 | GlaxoSmithKline, LLC. ($97,967) |
| 2017 | $137,280 | 90 | GlaxoSmithKline, LLC. ($61,770) |
All Payment Transactions
567 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $12,082.50 | General |
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $4,027.50 | General |
| 12/04/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $805.50 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $87.50 | General |
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,074.00 | General |
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| Category: Respiratory | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $891.42 | General |
| 10/22/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $8,356.85 | General |
| 10/02/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $1,165.97 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $113.92 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $113.92 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $76.78 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $58.97 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $58.97 | General |
| 10/02/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $18.09 | General |
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,013.75 | General |
| 09/20/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| 09/08/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $83.17 | General |
| 09/07/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,815.00 | General |
| 09/07/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $45.45 | General |
| 09/07/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $29.03 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH RESEARCH AGREEMENT | Novartis Pharmaceuticals Corporation | $3,281 | 1 |
| Publications Support | Teva Pharmaceuticals USA, Inc. | $1,604 | 1 |
| RUXOLITINIB VERSUS STANDARD THERAPY AS INITIAL TREATMENT IN HIGH RISK PV AND HIGH RISK ET | Novartis Pharmaceuticals Corporation | $1,125 | 1 |
| Rescue use COPD review article | Teva Pharmaceuticals USA, Inc. | $801.79 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $238.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 20 | 29 | $4,963 | $2,054 |
| 2022 | 1 | 23 | 34 | $4,380 | $2,500 |
| 2021 | 3 | 64 | 131 | $18,239 | $9,010 |
| 2020 | 2 | 51 | 65 | $6,441 | $3,208 |
Total Patients
158
Total Services
259
Medicare Billing
$16,771
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 20 | 29 | $4,963 | $2,054 | 41.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 23 | 34 | $4,380 | $2,500 | 57.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 38 | 73 | $8,882 | $5,741 | 64.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 41 | $7,954 | $2,427 | 30.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 14 | 17 | $1,403 | $841.80 | 60.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 26 | 30 | $3,583 | $1,667 | 46.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 25 | 35 | $2,858 | $1,541 | 53.9% |
About Dr. Meilan Han, MD
Dr. Meilan Han, MD is a Internal Medicine healthcare provider based in Ann Arbor, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457433369.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Meilan Han, MD has received a total of $909,137 in payments from pharmaceutical and medical device companies, with $146,033 received in 2024. These payments were reported across 567 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($587,245).
As a Medicare-enrolled provider, Han has provided services to 158 Medicare beneficiaries, totaling 259 services with total Medicare billing of $16,771. Data is available for 4 years (2020–2023), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Critical Care Medicine, Pulmonary Disease
- Location Ann Arbor, MI
- Active Since 10/19/2006
- Last Updated 01/17/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1457433369
Products in Payments
- DUPIXENT (Biological) $74,190
- STIOLTO RESPIMAT (Drug) $63,511
- SPIRIVA (Drug) $26,946
- BEVESPI AEROSPHERE (Drug) $24,364
- STIOLTO (Drug) $23,718
- NUCALA (Biological) $19,885
- BREZTRI (Drug) $16,669
- AirDuo Digihaler (Drug) $15,918
- FASENRA (Drug) $9,712
- AIRSUPRA (Drug) $8,356
- BREZTRI AEROSPHERE (Drug) $7,391
- OFEV (Drug) $7,210
- TRELEGY ELLIPTA (Drug) $6,366
- Yupelri (Drug) $3,537
- SPIRIVA RESPIMAT (Drug) $2,262
- TEZSPIRE (Biological) $1,478
- ANORO (Drug) $1,391
- JAKAFI (Drug) $1,125
- CHARTIS CATHETER (Device) $1,050
- ArmonAir Digihaler (Drug) $970.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Ann Arbor
Dr. Marschall Runge, Md, MD
Internal Medicine — Payments: $2.3M
Internal Medicine $2.3M
Terry Smith, M.d, M.D
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Harry Erba, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Dinesh Khanna, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Alexander Yevzlin, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Vallerie Mclaughlin, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M